Repurposed drugs in metabolic disorders

Current Topics in Medicinal Chemistry

Volumn 13, Issue 18, 2013, Pages 2386-2394

  Finsterer, Josef ^a   Frank, Marlies ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Drug development; Metabolic disorders; Metabolism; New indication; Reprofiling; Repurposing; Retasking

Indexed keywords

4 PHENYLBUTYRIC ACID; AMITRIPTYLINE; APOMORPHINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CICLETANINE; COLESEVELAM; DAPROPTERIN; DASATINIB; DULOXETINE; FLUOXETINE; GLIZONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; LADOSTIGIL; LITHIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OLANZAPINE; PIOGLITAZONE; PIOZ; PRAMIPEXOLE; QUETIAPINE; SAPROPTERIN; TETRACYCLINE DERIVATIVE; TETRAHYDROBIOPTERIN; UBIDECARENONE; UBIQUINONE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; CLINICAL TRIAL (TOPIC); DEPRESSION; DIABETES MELLITUS; DIASTOLIC HEART FAILURE; DRUG DESIGN; DRUG MECHANISM; DRUG REPOSITIONING; DRUG STRUCTURE; ENZYME DEFICIENCY; FIBROMYALGIA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERLIPIDEMIA; HYPERPHENYLALANINEMIA; HYPERTENSION; INTRAHEPATIC CHOLESTASIS; KIDNEY FAILURE; METABOLIC DISORDER; MUSCLE CRAMP; MYALGIA; MYELOID LEUKEMIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHENYLKETONURIA; PSYCHOSIS; PULMONARY HYPERTENSION; RHABDOMYOLYSIS; UREA CYCLE DISORDER; WEAKNESS;

ANIMALS; DRUG REPOSITIONING; HUMANS; METABOLIC DISEASES;

EID: 84887901946     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113136660166     Document Type: Article

References (71)

1. Xu, K.; Coté, T. R. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases. Brief. Bioinform, 2011, 12, 341-345.
2. DiMasa, J. A.; Hansen, R. W.; Grabowski, H. G.; Lasagna, L. Cost of Innovation in the Pharmaceutical Industry. J. Health Economics, 1991, 10, 107.
3. Sleigh, S. H.; Barton, C. L. "Repurposing Strategies for Therapeutics. " Pharm. Med, 2010, 24, 151-159.
4. Thöny, B.; Auerbach, G.; Blau, N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem. J, 2000, 347, 1-16.
5. Cáka, J. The role of nitric oxide in the hypothalamic control of LHRH and oxytocin release, sexual behavior and aging of the LHRH and oxytocin neurons. FOLIA HISTOCHEMICA ET CYTOBIOLOGICA 2005 Department of Functional Morphology, Division of Animal Anatomy, University of Warmia and Mazury, Olsztyn, Poland; 2005; page 4] http://fhc. amb. edu. pl/archives/fulltxt/vol44/44-1/03-12. pdf, (access May 2012).
6. Tadic, V.; Kasten, M.; Brüggemann, N.; Stiller, S.; Hagenah, J.; Klein, C. Dopa-Responsive Dystonia Revisited: Diagnostic Delay, Residual Signs, and Nonmotor Signs. Arch. Neurol, 2012, 17, 1-5.
7. Wu, G.; Meininger, C. J. Nitric oxide and vascular insulin resistance. Biofactors, 2009, 35, 21-27.
8. Channon, K. M. Tetrahydrobiopterin: regulator of endothelial nitric oxide synthase in vascular disease. Trends Cardiovasc. Med, 2004, 14, 823-827.
9. Alp, N. J.; Mussa, S.; Khoo, J.; Cai, S.; Guzik, T.; Jefferson, A.; Goh, N.; Rockett, K. A.; Channon, K. M. Tetrahydrobiopterindependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J. Clin. Invest, 2003, 112, 725-735.
10. Cunnington, C.; Van Assche, T.; Shirodaria, C.; Kylintireas, I.; Lindsay, A. C.; Lee, J. M.; Antoniades, C.; Margaritis, M.; Lee, R.; Cerrato, R.; Crabtree, M. J.; Francis, J. M.; Sayeed, R.; Ratnatunga, C.: Pillai, R.; Choudhury, R. P.; Neubauer, S.; Channon, K. M. Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation, 2012, 125, 1356-1366.
11. Khoo, J.; Zhao, L.; Alp, N. J.; Bendall, J. K.; Nicoli, T.; Rockett, K.; Wilkins, M. R.; Channon, K. M. Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation. 2005, 111,. 212633.
12. Fiege, B.; Ballhausen, D.; Kierat, L.; Leimbacher, W.; Goriounov, D.; Schircks, B.; Thöny, B.; Blau, N. Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. Mol. Genet. Metab, 2004, 81, 45-51.
13. Gordon, P.; Thomas, J. A.; Suter, R.; Jurecki, E. Evolving patient selection and clinical benefit criteria for sapropterin dihydrochloride (Kuvan®) treatment of PKU patients. Mol. Genet. Metab, 2012, 105, 672-676.
14. Gersting, S. W.; Staudigl, M.; Truger, M. S.; Messing, D. D.; Danecka, M. K.; Sommerhoff, C. P.; Kemter, K. F.; Muntau, A. C. Activation of phenylalanine hydroxylase induces positive cooperativity toward the natural cofactor. J. Biol. Chem, 2010, 285, 30686-30697.
15. Michals-Matalon, K. Sapropterin dihydrochloride, 6-R-L-erythro 5, 6, 7, 8-tetrahydrobiopterin, in the treatment of phenylketonuria. Expert Opin. Investig. Drugs, 2008, 17, 245-251.
16. Wick-Urban, B. Trotz Ketonurie normal essen. In: Pharmazeutische Zeitung Online 15, 2007, (access May 2012).
17. Merck Serono erhält Zulassungsempfehlung für Kuvan(R) in Europa. Pressemitteilung von Merck Serono, vom 26. September 2008.
18. Frye, R. E.; Huffman, L. C.; Elliott, G. R. Tetrahydrobiopterin as a novel therapeutic intervention for autism. Neurotherapeutics, 2010, 7, 241-249.
19. Moens, A. L.; Kietadisorn, R.; Lin, J. Y.; Kass, D. Targeting endothelial and myocardial dysfunction with tetrahydrobiopterin. J. Mol. Cell. Cardiol, 2011, 51, 559-563.
20. Crane, F. L. Biochemical functions of coenzyme Q10. J. Am. Coll. Nutr, 2001, 20, 591-598.
21. Silberman, G. A.; Fan, T. H.; Liu, H.; Jiao, Z.; Xiao, H. D.; Lovelock, J. D.; Boulden, B. M.; Widder, J.; Fredd, S.; Bernstein, K. E.; Wolska, B. M.; Dikalov, S.; Harrison, D. G.; Dudley, S. C. Jr. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation, 2010, 121, 519-528.
22. Ernster, L.; Dallner, G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta, 1995, 1271, 195-204.
23. Bhagavan, H. N.; Chopra, R. K. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic. Res, 2006, 40, 445-453.
24. Hirano, M.; Garone, C.; Quinzii, C. M. CoQ(10) deficiencies and MNGIE: Two treatable mitochondrial disorders. Biochim. Biophys. Acta, 2012, 1820, 625-631.
25. Quinzii, C. M.; Hirano, M. Primary and secondary CoQ(10) deficiencies in humans. Biofactors, 2011, 37, 361-365.
26. Salviati, L.; Trevisson, E.; Rodriguez Hernandez, M. A.; Casarin, A.; Pertegato, V.; Doimo, M.; Cassina, M.; Agosto, C.; Desbats, M. A.; Sartori, G.; Sacconi, S.; Memo, L.; Zuffardi, O.; Artuch, R.; Quinzii, C.; Dimauro, S.; Hirano, M.; Santos-Ocaña, C.; Navas, P. Haploinsufficiency of COQ4 causes coenzyme Q10 deficiency. J. Med. Genet, 2012, 49, 187-191.
27. Quinzii, C. M.; Hirano, M.; DiMauro, S. CoQ10 deficiency diseases in adults. Mitochondrion, 2007, 7(suppl), S122-S126.
28. Rötig, A.; Appelkvist, E. L.; Geromel, V.; Chretien, D.; Kadhom, N.; Edery, P.; Lebideau, M.; Dallner, G.; Munnich, A.; Ernster, L.; Rustin, P. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet, 2000, 356, 391-395.
29. Rahman, S.; Hargreaves, I.; Clayton, P.; Heales, S. Neonatal presentation of coenzyme Q10 deficiency. J. Pediatr, 2001, 139, 456-458.
30. Horvath, R. Update on clinical aspects and treatment of selected vitamin-responsive disorders II (riboflavin and CoQ(10). J. Inherit. Metab. Dis, 2012, 35, 679-687.
31. Cordero, M. D.; Alcocer-Gómez, E.; de Miguel, M.; Cano-García, F. J.; Luque, C. M.; Fernández-Riejo, P.; Fernández, A. M.; Sánchez-Alcazar, J. A. Coenzyme Q(10): a novel therapeutic approach for Fibromyalgia? case series with 5 patients. Mitochondrion, 2011, 11, 623-625.
32. Duncan, A. J.; Hargreaves, I. P.; Damian, M. S.; Land, J. M.; Heales, S. J. Decreased ubiquinone availability and impaired mitochondrial cytochrome oxidase activity associated with statin treatment. Toxicol. Mech. Methods, 2009, 19, 44-50.
33. 10 and cardiovascular disease: a review. J. Cardiovasc. Nurs, 2002, 16, 9-20.
34. Muraki, A.; Miyashita, K.; Mitsuishi, M.; Tamaki, M.; Tanaka, K.; Itoh, H. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance. J. Appl. Physiol, 2012, 113, 479-486.
35. Sikka, P.; Kapoor, S.; Bindra, V. K.; Sharma, M.; Vishwakarma, P.; Saxena, K. K. Statin intolerance: now a solved problem. J. Postgrad. Med, 2011, 57, 321-328.
36. Wyman, M.; Leonard, M.; Morledge, T. Coenzyme Q10: a therapy for hypertension and statin-induced myalgia? Cleve. Clin. J. Med, 2010, 77, 435-442.
37. 10-enzymes by clinically used adrenergic blockers of beta-receptors. Res. Comm. Chem. Pathol. Pharmacol, 1977, 17, 157-164.
38. Finsterer, J.; Gelpi, E. Mitochondrial disorder aggravated by propranolol. South. Med. J, 2006, 99, 768-771.
39. Chikhale, E. Welchol™ (colesevelam HCl) for oral suspension. Chemistry Reviews, Daiichi Sankyo, Inc, 2008.
40. Bays, H.; Dujovne, C. Colesevelam HCl: a non-systemic lipidaltering drug. Expert Opin. Pharmacother, 2003, 4, 779-790.
41. Zema, M. J. Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action. Core Evid, 2012, 7, 61-75.
42. Product Information: Welchol(TM), colesevelam hydrochloride. Sankyo Parke Davis, Parsippany, NJ, (PI revised 07/2000) reviewed 07/2000, (access June 2012).
43. Aggarwal, S.; Loomba, R. S.; Arora, R. R. Efficacy of colesevelam on lowering glycemia and lipids. J. Cardiovasc. Pharmacol, 2012, 59, 198-205.
44. Goldberg, R. B.; Rosenson, R. S.; Hernandez-Triana, E.; Misir, S.; Jones, M. R. Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus. J. Clin. Lipidol, 2012, 6, 318-324.
45. Ooi, C. P.; Loke, S. C. Colesevelam for type 2 diabetes mellitus. Cochrane Database Syst. Rev., 2012, 12, CD009361. doi: 10. 1002/14651858. CD009361. pub2, (access June 2012).
46. Drug patent watch. Drug patent expirations and intelligence. ACTOS. http://drugpatentwatch. com/ultimate/preview/tradename/index. php?query=ACTO, (access July 2012).
47. Momose, Y.; Meguro, K.; Ikeda, H.; Hatanaka, C.; Oi, S.; Sohda, T. Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds. Chem. Pharm. Bull. (Tokyo), 1991, 39, 1440-1445.
48. Gillies, P. S., Dunn, C. J. Pioglitazone. Drugs, 2000, 60, 333-343.
49. Nicolakakis, N.; Aboulkassim, T.; Ongali, B.; Lecrux, C.; Fernandes, P.; Rosa-Neto, P.; Tong, X. K.; Hamel, E. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferatoractivated receptor gamma agonist. J. Neurosci, 2008, 28, 9287-9296.
50. Heneka, M. T.; Sastre, M.; Dumitrescu-Ozimek, L.; Hanke, A.; Dewachter, I.; Kuiperi, C.; O'Banion, K.; Klockgether, T.; Van Leuven, F.; Landreth, G. E. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain, 2005, 128, 1442-1453.
51. Li, F.; Cai, Z.; Chen, F.; Shi, X.; Zhang, Q.; Chen, S.; Shi, J.; Wang, D. W.; Dong, N. Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products. Basic Res. Cardiol, 2012, 107, 306.
52. Agulnik, M.; Giel, J. L. Understanding Rechallenge and Resistance in the Tyrosine Kinase Inhibitor Era: Imatinib in Gastrointestinal Stromal Tumor. Am. J. Clin. Oncol, 2012, (in press).
53. Salaroli, A.; Loglisci, G.; Serrao, A.; Alimena, G.; Breccia, M. Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFR rearrangement and type 1 diabetes. Ann. Hematol, 2012, 91, 1823-1824.
54. Ono, K.; Suzushima, H.; Watanabe, Y.; Kikukawa, Y.; Shimomura, T.; Furukawa, N.; Kawaguchi, T.; Araki, E. Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus. Intern. Med, 2012, 51, 2763-2766.
55. Ito, Y.; Miyamoto, T.; Chong, Y.; Maki, T.; Akashi, K.; Kamimura, T. Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin. Int. J. Hematol., 2013, 97, 135-138.
56. Mucke, H. A. M. Dreug repositioning: extracting added value from prior R&D investments. Insight Pharma. Report, 2010.
57. Appleby, B. S.; Nacopoulos, D.; Milano, N.; Zhong, K.; Cummings, J. L. A Review: Treatment of Alzheimer's Disease Discovered in Repurposed Agents. Dement. Geriatr. Cogn. Disord, 2013, 35, 1-22.
58. Lauterbach, E. C.; Victoroff, J.; Coburn, K. L.; Shillcutt, S. D.; Doonan, S. M.; Mendez, M. F. Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J. Neuropsych. Clin. Neurosci, 2010, 22, 8-18.
59. Grote, H. E.; Bull, N. D.; Howard, M. L.; van Dellen, A.; Blakemore, C.; Bartlett, P. F.; Hannan, A. J. Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur. J. Neurosci, 2005, 22, 2081-2088.
60. Peng, Q.; Masuda, N.; Jiang, M.; Li, Q.; Zhao, M.; Ross, C. A.; Duan, W. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp. Neurol, 2008, 210, 154-163.
61. Duan, W.; Peng, Q.; Masuda, N.; Ford, E.; Tryggestad, E.; Ladenheim, B.; Zhao, M.; Cadet, J. L.; Wong, J.; Ross, C. A. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiol. Dis, 2008, 30, 312-322.
62. Jang, S.-W.; Liu, X.; Chan, C.-B.; Weinshenker, D.; Hall, R. A.; Xiao, G.; Ye, K. Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem. Biol, 2009, 16, 644-656.
63. Himeno, E.; Ohyagi, Y.; Ma, L.; Nakamura, N.; Miyoshi, K.; Sakae, N.; Motomura, K.; Soejima, N.; Yamasaki, R.; Hashimoto, T.; Tabira, T.; LaFerla, F. M.; Kira, J. Apomorphine treatment in Alzheimer mice promoting amyloid-α degradation. Ann. Neurol, 2011, 69, 248-256.
64. Appelskog, I. B.; Ammerpohl, O.; Svechnikova, I. G.; Lui, W. O.; Almqvist, P. M.; Ekström, T. J. Histone deacetylase inhibitor 4-phenylbutyrate suppresses GAPDH mRNA expression in glioma cells. Int. J. Oncol, 2004, 24, 1419-1425.
65. Iannitti, T.; Palmieri, B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R D, 2011, 11, 227-249.
66. Rubenstein, R. C.; Zeitlin, P. L. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am. J. Respir. Crit. Care Med, 1998, 157, 484-490.
67. Batshaw, M. L.; MacArthur, R. B.; Tuchman, M. Alternative pathway therapy for urea cycle disorders: twenty years later. J. Pediatr, 2001, 138(suppl 1), S46-S55.
68. nd; Feigenbaum, A.; Jomphe, C.; Marier, J. F.; Beliveau, M.; Mauney, J.; Dickinson, K.; Martinez, A.; Mokhtarani, M.; Scharschmidt, B.; Rhead, W. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate. Mol. Genet. Metab, 2011, 103, 323-329.
69. Gonzales, E.; Grosse, B.; Cassio, D.; Davit-Spraul, A.; Fabre, M.; Jacquemin, E. Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2. J. Hepatol, 2012, 57, 695-698.
70. Jacquemin, E. Progressive familial intrahepatic cholestasis. Clin. Res. Hepatol. Gastroenterol, 2012, 36(suppl 1), S26-S35.
71. Roy, A.; Ghosh, A.; Jana, A.; Liu, X.; Brahmachari, S.; Gendelman, H. E.; Pahan, K. Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease. PLoS One, 2012, 7, e38113. doi: 10. 1371/journal. pone. 0038113, (access September 2012).